The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...
A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...
The presentation "Measurable Residual Disease in AML using Oncomine NGS analysis" by Dr. Jong-Mi Lee from the College of Medicine at The Catholic University of Korea explores the application of ...
AlloHeme test accurately predicts relapse post-allo-HSCT in AML and MDS, with a median lead time of 36 days. The ACROBAT study involved 287 patients, showing significant predictive value of increased ...
Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
Today, OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results